Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) – subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial

The file will be sent to you via the Telegram messenger. It may take up to 1-5 minutes before you receive it.

Note: Make sure you have linked your account to Z-Library Telegram bot.

The file will be sent to your Kindle account. It may take up to 1–5 minutes before you receive it.

Please note: you need to verify every book you want to send to your Kindle. Check your mailbox for the verification email from Amazon Kindle.